

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2018

Site-1 protease regulates skeletal stem cell population and osteogenic differentiation in mice

Debabrata Patra

Washington University School of Medicine in St. Louis

Elizabeth DeLassus

Washington University School of Medicine in St. Louis

Jennifer Mueller

Washington University School of Medicine in St. Louis

Grazia Abou-Ezzi

Washington University School of Medicine in St. Louis

Linda J. Sandell

Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Patra, Debabrata; DeLassus, Elizabeth; Mueller, Jennifer; Abou-Ezzi, Grazia; and Sandell, Linda J., "Site-1 protease regulates skeletal stem cell population and osteogenic differentiation in mice." *Biology Open*. 7, 2. 1-13. (2018).

https://digitalcommons.wustl.edu/open_access_pubs/6649

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

RESEARCH ARTICLE

Site-1 protease regulates skeletal stem cell population and osteogenic differentiation in mice

Debabrata Patra^{1,*}, Elizabeth DeLassus², Jennifer Mueller¹, Grazia Abou-Ezzi³ and Linda J. Sandell^{1,4}

ABSTRACT

Site-1 protease (S1P) is a proprotein convertase with essential functions in the conversion of precursor proteins to their active form. In earlier studies, we demonstrated that S1P ablation in the chondrocyte lineage results in a drastic reduction in endochondral bone formation. To investigate the mechanistic contribution of S1P to bone development we ablated S1P in the osterix lineage in mice. S1P ablation in this lineage results in osteochondrodysplasia and variable degrees of early postnatal scoliosis. Embryonically, even though Runx2 and osterix expression are normal, S1P ablation results in a delay in vascular invasion and endochondral bone development. Mice appear normal when born, but by day 7 display pronounced dwarfism with fragile bones that exhibit significantly reduced mineral density, mineral apposition rate, bone formation rate and reduced osteoblasts indicating severe osteopenia. Mice suffer from a drastic reduction in bone marrow mesenchymal progenitors as analyzed by colony-forming unit-fibroblast assay. Fluorescence-activated cell sorting analysis of the skeletal mesenchyme harvested from bone marrow and collagenase-digested bone show a drastic reduction in hematopoietic lineage-negative, endothelial-negative, CD105⁺ skeletal stem cells. Bone marrow mesenchymal progenitors are unable to differentiate into osteoblasts *in vitro*, with no effect on adipogenic differentiation. Postnatal mice have smaller growth plates with reduced hypertrophic zone. Thus, S1P controls bone development directly by regulating the skeletal progenitor population and their differentiation into osteoblasts.

This article has an associated First Person interview with the first author of the paper.

KEY WORDS: Site-1 protease, Skeletal stem cells, Osteopenia, Osterix

INTRODUCTION

Site-1 protease (S1P), coded by the *Mbtps1* gene (*membrane bound transcription factor protease, site 1*), is a proprotein convertase with vital roles in lipid homeostasis and the unfolded protein response (UPR) (Brown et al., 2000; Eberlé et al., 2004). These pathways are

fundamental to cellular homeostasis and involve the activation of latent, endoplasmic reticulum (ER)-membrane-bound transcription factors. Of late, newer roles have been attributed to S1P and the transcription factors that it processes. OASIS (old astrocyte specifically induced substance), a S1P substrate, is necessary for type I collagen (*Col1a1* and *Col1a2*) expression in mice, critical for bone formation (Murakami et al., 2009). The processing of *N*-acetylglucosamine-1-phosphotransferase α/β -subunit precursor by S1P is essential to lysosome biogenesis, which impacts skeletal development (Marschner et al., 2011). In the zebrafish *gonzo* phenotype, S1P ablation results in both cartilage and lipid phenotypes, but ablation of SCAP [the SREBP (sterol responsive element binding protein) cleavage activating protein] results only in lipid phenotypes (Schlombs et al., 2003). This indicates that not all S1P functions are lipid regulated or mediated through transcription factors, and is indicative of additional roles for S1P that impact skeletal development.

We have demonstrated previously that S1P is essential to skeletal development. S1P ablation in osteochondroprogenitors in mice (*S1P^{cko}*; via *Col2-Cre*) results in chondrodysplasia (Patra et al., 2014b, 2007). These mice show abnormal cartilage development with type IIB procollagen (pro-Col IIB) entrapment in the chondrocyte ER and a drastic reduction in type II collagen (Col II) protein in the cartilage. The pro-Col IIB entrapment is so drastic that it induces UPR and chondrocyte apoptosis; these mice also lack endochondral bone. Postnatal ablation of S1P in chondrocytes resulted in loss of hypertrophic chondrocyte (HC) differentiation, elimination of the primary growth plate and loss of bone growth (Patra et al., 2011). In these studies, the cartilage phenotype was deemed a primary consequence of the mutation and bone developmental defects a consequence of cartilage defect.

To investigate if S1P has a direct role in bone development, we ablated S1P in the osterix (*Osx*) lineage using *Osx-Cre* mice (Rodda and McMahon, 2006). *Osx* is a transcription factor expressed in late stages of endochondral ossification (Nishimura et al., 2012). It is expressed strongly in osteoblast precursors and required for osteoblast differentiation; it is also expressed in pre-HCs, where it is required for maturation. Our observation that postnatal S1P ablation obliterates HCs, coupled with the fact that HCs can transdifferentiate into osteoblasts (Park et al., 2015; Yang et al., 2014; Zhou et al., 2014), presented an opportunity to address the importance of S1P to bone development via its ablation in the *Osx* lineage. In this study, we show that S1P ablation in the *Osx* lineage drastically downregulates postnatal bone development resulting in osteopenia, indicating a direct role for S1P in bone development. Our mechanistic characterizations show that S1P is necessary to maintain the skeletal mesenchyme in the postnatal bone marrow. It is also required for the differentiation of mesenchymal progenitors into osteoblasts. Thus S1P is needed at multiple stages during bone development.

¹Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. ²Department of Biochemistry, Washington University School of Medicine, St. Louis, MO 63110, USA. ³Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO 63110, USA. ⁴Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

*Author for correspondence (debabratapatra@wustl.edu)

DOI: 10.1242/bio.032094

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

RESULTS

S1P ablation in the *Osx* lineage results in dwarfism

To investigate roles for S1P in bone development, we used *Osx-Cre* mice to ablate S1P in the *Osx* lineage. Homozygous S1P-ablation in the *Osx* lineage (*S1P^{cko-Osx}* or *Cko*) results in dwarfism with very fragile bones that often break easily from normal cage activities. Heterozygously ablated *S1P^{+/-Osx}* (Het) mice are intermediate in size to wild-type (WT) (*S1P^{+/+}*) and *S1P^{cko-Osx}* mice and are smaller than *Osx-Cre* mice (Fig. 1A). *S1P^{cko-Osx}* mice often display varying degrees of scoliosis that at times is severe (Fig. 1B; Fig. S1) and is seen as early as 7–10 days postnatally (Fig. S1).

To investigate whether dwarfism is related to aberrant bone development we analyzed the skeletons of these mice by micro-computed tomography (μ CT). Scanned images were developed by OsiriX software and Jet color scheme to generate bone mineral density (BMD) heat maps, in which yellowish-orange signifies high, and blue low, values for BMD. Fig. 2A and Fig. S2 show that bone development deviates very early and rapidly from normal, postnatally. When compared to postnatal day (P) 1 mice (Fig. S2A), P7 *S1P^{cko-Osx}* (*Cko*) mice are severely osteopenic with drastically reduced BMD and smaller axial (Fig. 2A) and appendicular (Fig. 2B) skeletal elements; *S1P^{+/-Osx}* (Het) mice are intermediate to WT and *S1P^{cko-Osx}* mice (Fig. 2A,B). While no noticeable differences in size and BMD are seen in P1 (Fig. S2A), reductions in size and BMD are visible at P5 in S1P-ablated mice in comparison to *Osx-Cre* or WT mice (Fig. S2B). In P7 *Cko* mice, the mid-diaphyseal cortical bone is smaller in width with thinner cortical bone when compared to WT mice (Fig. 2C); Het mice, though showing no decrease in cortical bone thickness, are smaller in width when compared to WT or *Osx-Cre* mice (Fig. 2C).

In dynamic histomorphometric analysis performed by calcein (green)-alizarin (red) double labeling of bone, *Cko* mice exhibited a significant reduction in both mineral apposition rate (MAR) (Fig. 2E,F) and bone formation rate/bone surface (BFR/BS) (Fig. 2G) that correlates well with the decrease in osteoblasts seen on the endosteal surface of the cortical bone (Fig. 2D). However, there was no change in osteoclast surface/bone surface (Oc.S/BS) (Fig. S3A). These data indicate that S1P ablation induces osteopenia very early postnatally, as seen by the significant decrease in bone volume fraction (BV/TV) and volumetric BMD for the trabecular (Fig. S3B,C) and cortical bone (Fig. S3D–F) in P7 mice, and a drastic reduction in pMOI (a measure of resistance to torsional force), confirming the fragile nature of the bone. To analyze how these differences correlate with molecular changes in the bone, we harvested RNA from the calvaria and long bones (femur/tibia) of P10 and P21 mice, and analyzed for mature osteoblast markers by quantitative real-time polymerase chain reaction (qPCR). Both P10 (not shown) and P21 mice showed significant reductions in *type I procollagen (proColla1)*, *Bglap (osteocalcin)* and *alkaline phosphatase (Alp)* expression in the calvaria (Fig. S3G) and primarily *proColla1* in bone (Fig. S3H). These data indicate that S1P ablation in the *Osx* lineage results in lower mature osteoblast numbers in the postnatal bone, and is responsible for reduced bone growth and dwarfism.

To verify that these phenotypes were caused by S1P ablation in the *Osx* lineage in the developing skeleton, we performed *in situ* hybridization (ISH) analysis for *Mbtps1-exon 2*, the floxed allele in *S1P^{+/+}* mice. Significant S1P ablation was observed in both pre-HCs and HCs in both *S1P^{+/-Osx}* and *S1P^{cko-Osx}* mice, as seen by lack of *Mbtps1-exon 2* expression (Fig. S4A–J). Notably, as Cre is




Fig. 1. Mice with S1P ablation in the *Osx* lineage. (A) S1P ablation in the *Osx* lineage results in short-statured mice. Mice are 21 days postnatal (P21). (B) Images from μ CT scans of P21 mice showing severe scoliosis in *S1P^{cko-Osx}*. Scale bar: 2.5 mm.




Fig. 2. Osteopenia due to S1P ablation in the *Osx* lineage. (A,B) BMD heat maps generated for P7 *Osx-Cre*, *WT (S1P^{f/f})*, *S1P^{+/-}-Osx (Het)* and *S1P^{cko}-Osx (Cko)* spines (A) and femora (B) from μ CT scans processed by OsiriX using Jet color scheme (window location, 1440; window width, 1890; for all images). A typical representation from several litters ($N=3$) is shown. (C) Mid-diaphyseal femoral cortical bone from μ CT scans in P7 mice. (D) Gold-trichrome staining for osteoblasts (reddish) lining the endosteal in P28 cortical bone, drastically reduced in the *Cko*. Arrow in *Cko* points to a lone osteoblast. (E) Calcein (green)-alizarin (red) double-labeling of the endosteal surface of the femoral cortical bone in P28 mice (BM, bone marrow). (F) MAR (mean \pm s.d.; $N=5$). * $P<0.0004$ compared to *WT/Osx-Cre*; # $P=0.006$ (compared to *Het*). (G) BFR/BS (mean \pm s.d.; $N=5$). * $P=0.0004$ (compared to *WT*); # $P=0.014$ (compared to *Het/Osx-Cre*). Scale bars: (A) 2.5 mm; (B) 1 mm; (C) 0.25 mm; (D,E) 25 μ m.

expressed as a GFP-fusion protein, GFP expression is observed in pre-HCs/HCs that overlaps with zones of S1P ablation (compare Fig. S4I,J with L,M); GFP is also seen in the perichondrium (arrows, Fig. S4L,M). These data confirmed efficient S1P ablation in zones of *Osx* expression, and that GFP expression in our mouse model is a good surrogate for S1P ablation as reported earlier (Rodda and McMahon, 2006).

S1P ablation in the *Osx* lineage delays endochondral bone development

To investigate why S1P ablation in the *Osx* lineage results in osteopenia, we first investigated embryonic bone development. At embryonic day (E) 15.5, WT mice showed characteristic development of the primary ossification center (POC) with normal endochondral bone development (Fig. 3A). In *S1P^{+/f-Osx}* and *S1P^{cko-Osx}* mice, however, endochondral bone development is delayed. In *S1P^{+/f-Osx}* mice, only the beginning of vascular invasion is seen at E15.5 (arrow, Fig. 3A); normal endochondral bone development is observed later at E16.5. In *S1P^{cko-Osx}* mice, at E15.5 and E16.5 only cartilage is seen where normally the POC would develop (brackets, Fig. 3A), with no evidence of vascular invasion; endochondral bone development is seen later at E17.5. Even though normal mineralization of the ECM is seen in all three genotypes at E15.5 (Fig. 3B), immunofluorescence (IF) analysis for the PECAM-1 antigen at E16.5 showed that vascular invasion is delayed in *S1P^{cko-Osx}* (Fig. 3C).

To investigate this delay, we performed ISH analysis of several molecular markers of the growth plate in E16.5 femora (Fig. 4). In S1P-ablated mice, *Ihh* (in pre-HCs) and *Col10a1* (in HCs) expression is observed in the expected zones; the thickness of the zones and expression levels of *Ihh* and *Col10a1* are similar. *Col1a1* expression is seen in the cortical bone and endochondral bone (arrow, Fig. 4) in the WT, but is primarily restricted to the cortical bones in mutant mice. In *S1P^{+/f-Osx}* mice, moderate *Col1a1* expression is seen in the POC, suggesting that endochondral bone development has begun but is not as mature as in the WT. In *S1P^{cko-Osx}* mice, the presumptive POC shows primarily chondrocyte-derived *MMP13* expression with faint tracings of vascular invasion by *Col1a1*-positive bone progenitors. Consequently, *MMP9* expression is seen only in the cortical bone in *S1P^{cko-Osx}*, confirming its developmental lag. *S1P^{cko-Osx}* mice display stronger *VEGF* expression than WT, presumably upregulated to counter the delay in vascular invasion. These data indicate that chondrocyte maturation during development is not affected, despite the absence of S1P in the *Osx* lineage. Morphological and ISH analysis performed in E16.5 *Osx-Cre* (*S1P^{+/+}*) control mice show robust endochondral bone development similar to WT mice (Fig. S5), indicating that the defects seen in *S1P^{+/f-Osx}* and *S1P^{cko-Osx}* mice are due to S1P ablation.

Next, we analyzed the embryonic cartilage growth plate for Col II protein. We performed double-labeled IF for Col IIA and Col II triple helical domain (THD; the mature processed Col II in the matrix) (Fig. S6) at E16.5. Our previous studies had demonstrated that S1P ablation in the chondrocyte lineage resulted in intracellular Col II entrapment with abnormal cartilage that impeded endochondral bone development (Patra et al., 2014a, 2007). However, S1P-ablation in the *Osx* lineage results in cartilage matrix very similar to WT. In the resting (not shown) and proliferating zones (zones where S1P is not ablated), the cartilage matrix is identical in all three genotypes, with Col IIA (green) and Col II THD (red) distributed identically (Fig. S6A-C) with no intracellular Col II entrapment. As S1P ablation is restricted to the pre-HCs/HCs, Col II entrapment is observed in these cells but only

in *S1P^{cko-Osx}* (arrows, Fig. S6F). In the WT and *S1P^{+/f-Osx}* mice, Col II THD (red) is seen primarily as clumps released from cells (arrows, Fig. S6D,E). In the chondrocyte-derived *MMP-13*-expressing zone present only in the *S1P^{cko-Osx}* growth plate, the matrix is made primarily of Col IIA (green) with very little evidence of Col II entrapment (Fig. S6G). Double-labeled IF for pro-Col IIB and Col II THD demonstrated that the trapped collagen is pro-Col IIB, where the signals from THD (red) overlap with signals from pro-Col IIB (green) resulting in yellow colocalization signals (arrows, Fig. S6I). However, this entrapment restricted to the hypertrophic zone does not trigger apoptosis (not shown) or obliterate the growth plate. Thus, Col II entrapment is not a defining feature of this mutant phenotype, suggesting other mechanisms at play.

S1P ablation in the *Osx* lineage reduces osteoblast development via a downregulation of mesenchymal progenitors

Next, we studied the embryonic osteoblast lineage by analyzing for Runx2 (Ducy et al., 1997; Komori et al., 1997; Otto et al., 1997) and *Osx* (Nakashima et al., 2002), transcription factors that have vital roles in osteoblastogenesis. Double-labeled IF for Runx2 (red) and Col II THD (green) in E15.5 femora demonstrated that, like WT, both *S1P^{+/f-Osx}* and *S1P^{cko-Osx}* mice show normal Runx2 expression in pre-HCs/HCs of the growth plate (Fig. 5A-C) and in the perichondrium (Fig. 5D-F). Likewise, ISH analysis for *Sp7* (*Osx*) in E15.5 femora demonstrated normal *Sp7* expression in all three genotypes (Fig. 5G-I), though the expression pattern is different, reflecting their developmental lag (Fig. 3A). Consequently, normal type I collagen protein (Col I) deposition is seen in the bone collar of *S1P^{+/f-Osx}* and *S1P^{cko-Osx}* mice as in the WT (Fig. 5J-L). We also investigated components of the Wnt/ β -catenin signaling pathway that have important roles in osteoblast differentiation (Hill et al., 2005; Hu et al., 2005; Rodda and McMahon, 2006). Using protein lysates made from the hind limbs of E14.5 mice, we investigated phosphorylation levels of Akt and GSK-3 β and total β -catenin levels in immunoblots. Identical levels of Akt and GSK-3 β phosphorylation and β -catenin levels are observed in protein lysates from all three genotypes (Fig. S7) indicating normal Wnt/ β -catenin signaling in mutant mice.

Next, we investigated if skeletal progenitors were affected. The bone marrow is a niche for mesenchymal-derived skeletal stem cells (SSCs) and recent studies have identified specific SSCs with temporal and lineage-specific contributions to skeletal development (Chan et al., 2015; Worthley et al., 2015). Besides, *Osx* is active in bone marrow stromal cells (BMSCs) (Chen et al., 2014; Mizoguchi et al., 2014), suggesting that S1P ablation in these cells could affect the postnatal bone marrow compartment and, consequently, skeletal development. Therefore, we first analyzed the ability of BMSCs from P21 WT, *S1P^{+/f-Osx}* (Het) and *S1P^{cko-Osx}* (Cko) mice to form colony-forming unit-fibroblasts (CFU-F), a measure of mesenchymal progenitors in the bone marrow. While the WT and *S1P^{+/f-Osx}* mice showed similar CFU-F capabilities, this capability was significantly reduced in *S1P^{cko-Osx}* mice (Fig. 6A). Next, we analyzed if the downregulation in CFU-F correlates with a downregulation of SSCs. SSCs have been defined as CD105-expressing (CD105⁺) cells that are triple negative for CD45, Ter-119 and CD31 (Chan et al., 2015; Worthley et al., 2015). CD45 is expressed on most hematopoietic cells, except maturing erythroid cells that express Ter-119; CD31 is expressed on endothelial cells. Using fluorescent-conjugated antibodies for CD45, Ter-119, CD31 and CD105, we analyzed LIN⁻ (CD45⁻, Ter-119⁻), CD31⁻, CD105⁺ cells in the bone marrow/collagenase-digested bones from




Fig. 3. (A) Delayed endochondral ossification in *S1P^{+/-}Osx* and *S1P^{cko}Osx* mice. Safranin O/Fast Green/Hematoxylin-stained femora from WT, *S1P^{+/-}Osx* and *S1P^{cko}Osx* at embryonic time points. Arrow points to the beginnings of vascular invasion in *S1P^{+/-}Osx* at E15.5 but the absence of endochondral bone. Brackets denote approximate boundaries of the central expanding zone of cells in *S1P^{cko}Osx* in the absence of endochondral bone, at E15.5 and E16.5. (B) von Kossa staining for mineralization of E15.5 femora. (C) IF for PECAM-1 at E16.5 (c, cartilage; b, bone). Arrow points to the beginning of vascular invasion in *S1P^{cko}Osx*. Scale bars: 100 μ m.

P21 mice by fluorescence-activated cell sorting (FACS) analysis. In parallel to that seen for CFU-F, WT and *S1P^{+/-}Osx* mice showed similar levels of LIN⁻, CD31⁻, CD105⁺ SSCs, while *S1P^{cko}Osx* mice demonstrated a drastic reduction in these SSCs (Fig. 6B-D). Given the similar numbers of SSCs in WT and *S1P^{+/-}Osx* mice, it was puzzling that *S1P^{+/-}Osx* mice are smaller than WT or *Osx-Cre*

mice. Therefore we analyzed the capacity of BMSCs for osteogenic differentiation *in vitro* (Fig. 6E). WT mice showed strong osteogenic differentiation *in vitro* as seen by the presence of mineralized bone nodules. Control *Osx-Cre* (*S1P^{+/+}*) mice also demonstrated osteogenic differentiation (though this was reduced when compared to WT). In contrast, neither *S1P^{+/-}Osx* or *S1P^{cko}Osx*




Fig. 4. ISH analyses of the growth plate in E16.5 femora for *Ihh*, *Col10a1*, *MMP13*, *Col1a1* and *MMP9*, and in E15.5 femora for *VEGF*. Brackets denote approximate boundaries of the central expanding zone of cells in *S1P^{cko-Osx}* (also see Fig. 3A). Scale bars: 250 μ m.

mice were able to demonstrate osteogenic differentiation. To analyze if this was a generic progenitor issue, we analyzed if BMSCs were capable of undergoing adipogenesis *in vitro* (Fig. 6E). Interestingly, both *S1P^{+f-Osx}* and *S1P^{cko-Osx}* mice demonstrated adipogenic differentiation similar to *Osx-Cre* and WT mice. These data indicate a specific requirement for S1P not only to maintain the SSC population but also for their osteogenic differentiation.

Interestingly, we found the presence of many GFP-expressing (GFP⁺) cells in the bone marrow of *S1P^{cko-Osx}* (Cko) mice, which are absent in WT or Het mice (Fig. 7), or age-matched *Osx-Cre* mice (Fig. S8). Absence of GFP⁺ cells in the WT (which do not carry the *Osx-Cre* transgene) is expected. But GFP⁺ cells are missing in the bone marrow of *S1P^{+f-Osx}* (Het) (Fig. 7) or *Osx-Cre* mice (Fig. S8) that carry the transgene, even though these mice show GFP⁺ chondrocytes in the hypertrophic zone of the growth plate (arrows, Fig. S8). These GFP⁺ cells do not express osteocalcin (Ocn, a marker of mature osteoblast), though Ocn was detected on bone surfaces (arrow, Fig. 7D), and often appeared arranged in a rosette-like structure in the bone marrow (arrow, Fig. 7E). To study if the absence of S1P induces apoptosis in bone marrow constituents, we analyzed apoptosis by FACS using a fluorescent-labeled Annexin V conjugate,

which detects apoptosis-induced externalization of phosphatidylserine on the cell surface. However, no more apoptosis was detected in the Cko bone marrow than that seen in WT or Het (Fig. 7F). These GFP⁺ cells in the Cko bone marrow indicate that these cells are in the *Osx* lineage and that their detection is possible due to an arrest in differentiation, presumably to the osteoblast lineage. The absence of these cells in the WT, Het and *Osx-Cre* mice indicates conditions favorable for SSC maintenance and maturation in these mice. qPCR analysis of RNA harvested from the bone marrow showed significant decrease in the expression of *proColla1*, *Bglap*, *Alp*, *Runx2* and also *Col2a1* (a marker for osteochondroprogenitors) in *S1P^{cko-Osx}* when compared to WT and *S1P^{+f-Osx}* mice (Fig. 7G), an observation that parallels CFU-F and SSC levels seen in *S1P^{cko-Osx}* mice. These data collectively indicate that S1P ablation in the *Osx* lineage adversely affects bone development by downregulating osteoprogenitors and their differentiation.

S1P ablation in the *Osx* lineage reduces the postnatal growth plate

SSCs that contribute to the osteoblast lineage, downregulated in *S1P^{cko-Osx}* mice, also contribute to the chondrocyte lineage (Chan




Fig. 5. Molecular analysis of embryonic bone development. IF for Runx2 (red; A-F), Col II THD (green, A-C), and Col I (red, J-L) in E15.5 femora. D-F are higher magnification images of A-C (magnified region outlined in A-C; shown without signals from Col II). ISH analysis for *Sp7* (*Oss*) in E15.5 femora (G-I). Scale bars: (A-C, J-L) 100 µm; (D-F) 10 µm; (G-I) 250 µm.

et al., 2015; Worthley et al., 2015). Therefore we investigated if S1P ablation affects the postnatal cartilage and growth plate (Fig. 8). The epiphyseal cartilage and growth plate in WT, S1P^{+f-Osx} and S1P^{cko-Osx} mice look identical to each other up to 5 days postnatally. The WT and S1P^{+f-Osx} mice showed identical phenotypes in this analysis and therefore only WT and S1P^{cko-Osx} are shown. At P5, with the exception of the bone width that is smaller in S1P^{cko-Osx} mice, the growth plate and epiphyseal cartilage are indistinguishable (Fig. 8A,B) (P5 S1P^{cko-Osx} mice are however smaller than WT, Fig. S2B). The WT shows incipient secondary ossification center (SOC) at P7 that develops further at P10 (arrows, Fig. 8C,E). However, the SOC is completely absent even at P10 in S1P^{cko-Osx} mice; it develops very slowly and even at P21 the epiphyseal cartilage in the SOC is not completely replaced by trabecular bone (Fig. S8C). The hypertrophic zone is smaller in S1P^{cko-Osx} (bracket, Fig. 8F) when compared to WT (Fig. 8E).

To investigate if this was induced by abnormal Col II deposition, we analyzed the epiphyseal cartilage by double-labeled IF for Col IIA and Col II THD as above. No marked differences between WT and S1P^{cko-Osx} mice is seen at any stage in Col II deposition (P5 shown as an example, Fig. 8G,H). However, S1P^{cko-Osx} showed extensive chondrocyte apoptosis in the epiphyseal cartilage at P7 (arrow, Fig. 8J), just above the hypertrophic zone of the growth plate. In previous studies, apoptosis was effected by abnormal pro-Col IIB entrapment that induced UPR and delayed SOC formation (Patra et al., 2011). However, no abnormal Col II entrapment was observed at P5 (Fig. 8G,H) (or other stages, not shown). Chondrocyte apoptosis overlapped with columnar cells of the growth plate (which normally mature to HCs). ISH analysis showed that while *Col10a1* expression is observed in the presumptive SOC (asterisk) and is uniform in the WT growth plate (Fig. 8K), it is

completely missing in the presumptive SOC (asterisk) in S1P^{cko-Osx} and is patchy in the hypertrophic zone with large areas missing *Col10a1* expression (arrow, Fig. 8L). Apoptotic death of chondrocytes would preclude their maturation to HCs that would keep this zone small in S1P^{cko-Osx}. Recent studies demonstrated that Gremlin1⁺ cells (Worthley et al., 2015) and CAR (Cxcl12-abundant reticular) cells are a source of chondrocyte progenitors (Omatsu et al., 2010). To investigate growth plate chondrocytes further in light of the decline of the hypertrophic zone and non-uniform expression of *Col10a1*, we analyzed Cxcl12 and Gremlin1 expression in the P21 growth plate. Both WT and S1P^{cko-Osx} show expression for Cxcl12 and Gremlin1 in HCs, characteristically missing in younger, proliferative chondrocytes (Fig. 8M-P). Similar to *Col10a1* expression, the WT has a bigger zone of Cxcl12- (Fig. 8M) and Gremlin1-expressing cells (Fig. 8O) than S1P^{cko-Osx}. Like the hypertrophic zone (hz) in P7 mice (Fig. 8F,L), Cxcl12- (Fig. 8N) and Gremlin1-expressing (Fig. 8P) zones are greatly reduced in S1P^{cko-Osx}. These observations confirm the significant loss of postnatal growth plate chondrocytes and of the hypertrophic zone in these mice. S1P^{cko-Osx} show a larger number of Cxcl12- and Gremlin1-expressing chondrocytes at the junction of the epiphyseal bone with the growth plate (arrow, Fig. 8N,P) than the WT at this junction. This expression is in chondrocytes left over from the incompletely replaced epiphyseal cartilage in S1P^{cko-Osx} that is otherwise efficiently replaced by bone in the WT (Fig. S8C).

DISCUSSION

S1P has emerged as a critical regulator of mammalian skeleton development. It is a fundamental component of the regulated intramembrane proteolysis system where it plays an active role along with S2P (*Mbtps2*) protease in processing precursor proteins




Fig. 6. Downregulation of SSCs in S1P^{cko-Osx}. (A) Enumeration of CFU-F in P21 WT, S1P^{+f-Osx} (Het) and S1P^{cko-Osx} (Cko) mice. Data shown as percent of WT to normalize between biological repeats (mean±s.d.; **P*<0.005 or not significant (ns) when compared to WT; *N*=3). (B,C) Scatter plot of FACS analysis for SSCs from P21 WT (B) and S1P^{cko-Osx} (C). LIN⁻, CD31⁻, CD105⁺ cells are demarcated by an ellipse. A typical result is shown. (D) Enumeration of LIN⁻, CD31⁻, CD105⁺ SSCs. Data shown as percent of WT (mean±s.d.; **P*<0.001 or ns when compared to WT; *N*=4). (E) *In vitro* osteogenic and adipogenic differentiation assays with BMSCs from P21 mice. Typical results are shown from *N*=3.

to their active form (Brown and Goldstein, 1999; Eberlé et al., 2004). Even though S1P mutations in humans are yet to be reported, mutations in SREBP-2 (a major S1P/S2P substrate) are linked to osteoarthritis pathogenesis in humans (Kostopoulou et al., 2012), and mutations in S2P are linked to osteogenesis imperfecta (Lindert et al., 2016). S1P therefore participates in a major homeostatic pathway needed for skeletal development and maintenance. In this study we demonstrated that S1P has a direct role in bone development. Our studies on S1P in the *Osx* lineage have identified a cellular mechanism where S1P is required to maintain LIN⁻, CD31⁻, CD105⁺ SSCs of the skeletal mesenchyme, which are precursors for chondrocyte and osteoblast lineages and for osteoblast differentiation.

S1P ablation in the *Osx* lineage results in short-statured mice, for which the extensiveness of their short stature correlates with the degree of ablation, with the heterozygous S1P^{+f-Osx} showing an intermediate size between the WT/*Osx-Cre* and S1P^{cko-Osx}. S1P^{cko-Osx} mice suffer from osteochondrodysplasia as both chondrocyte and osteoblast lineages are affected, contributing to declining bone growth. Part of the reason could be due to a lack of

OASIS activity. OASIS, an established substrate for S1P, is a transcription factor for *Colla1* and *Colla2* genes (Murakami et al., 2009). However, while *OASIS*^{-/-} mice are also smaller than WT, this reduction in size is not as severe as seen in S1P-ablated mice. Furthermore, qPCR analysis of RNA isolated from the calvaria of *OASIS*^{-/-} mice demonstrated a reduction only in *Colla1* and *Colla2* expression, while *Bglap* and *Alp* were upregulated. However, S1P-ablated mice show a drastic decrease in size that can be discerned as early as P5 and a reduction in the expression of *proColla1*, *Bglap* and *Alp*. Thus, unlike *OASIS*^{-/-} mice, S1P ablation in the *Osx* lineage mediates a global downregulation of the osteoblast lineage, consistent with a role in maintaining SSC population, and not via OASIS functions.

During embryonic bone development, at E13.5, before the formation of bone marrow cavity, *Osx*⁺ progenitors from the perichondrium migrate into the POC, along with blood vessels (Maes et al., 2010; Mizoguchi et al., 2014). Because of the direct association between vascular invasion and invading osteoprogenitors that initiates POC development, a defect in either of these two components could induce a delay in endochondral bone development.




Fig. 7. Analysis of the bone marrow compartment. (A–C) GFP⁺ cells in the bone marrow of P21 S1P^{cko-Osx} (Cko) femur, absent in WT or Het (also see Fig. S8). Dashed lines show junction of bone marrow with cortical bone. (D) IF for osteocalcin (Ocn, red) in P21 Cko. (E) GFP⁺ rosettes (arrow) in the Cko bone marrow (blue, DAPI-stained nuclei). (F) FACS analysis for apoptosis (% cells labeled with Annexin V conjugate) in cells from P21 bone marrow (mean±s.d.; N=3). (G) qPCR analysis for *Col2a1*, *proCol1a1*, *Bglap*, *Alp* and *Runx2* with RNA harvested from P21 bone marrow (mean±s.d.; N=3; **P*<0.05, #*P*<0.005, ##*P*<0.001, or *ns* when compared to WT). Scale bars: (A–C) 100 µm; (D,E) 10 µm.

A decrease or a defect in perichondrial osteoprogenitors is plausible due to S1P ablation in these cells (due to *Osx-Cre* activity in perichondrium deduced from the presence of GFP⁺ cells). A decrease/defect in perichondrial osteoprogenitors could induce a delay, owing to lack of adequate numbers of functional progenitors required to set up the POC, or to crosstalk with the vascular invasion mechanism. A delay in vascular invasion could be induced by the entrapped pro-Col IIB in the hypertrophic zone in S1P^{cko-Osx} where vascular invasion takes place. S1P^{cko} mice (*Col2-Cre* driven) suffered from a complete lack of vascular invasion where pro-Col IIB entrapment was absolute (Patra et al., 2014a, 2007). This suggests that clearing of the entrapped pro-Col IIB in this zone by UPR may be necessary before vascular invasion can begin. In contrast to S1P^{cko} mice, the limited pro-Col IIB entrapment in S1P^{cko-Osx} allows the removal of the trapped pro-Col IIB

without inducing apoptosis. However, a delay in vascular invasion is also seen in the heterozygous S1P^{+/f-Osx} mice, which do not exhibit any pro-Col IIB entrapment. Thus, S1P^{+/f-Osx} mice may suffer from only a lack of adequate *Osx*⁺ perichondrial progenitor functions, while a defect in *Osx*⁺ perichondrial progenitors coupled to the entrapped pro-Col IIB may induce a more pronounced delay in vascular invasion seen in S1P^{cko-Osx} mice.

Lineage tracing experiments have demonstrated the presence of temporally distinct fetal, perinatal and adult *Osx*⁺ bone progenitors (Maes et al., 2010; Mizoguchi et al., 2014). Fetal perichondrial *Osx*⁺ progenitors contribute significantly to perinatal (~8 day old mice) bone and BMSCs, but not to adult bone or bone marrow. However, perinatal *Osx*⁺ progenitors contribute to perinatal bone development and to long-lived stromal cells that contribute to




Fig. 8. Downregulation of the chondrocyte lineage in *S1P^{cko}-Osx* mice. (A-F) Safranin O-stained sections of the growth plate and epiphyseal cartilage in P5 (A, B), P7 (C, D) and P10 (E, F) femora (distal end). Arrows in C and E point to the developing SOC. (G, H) Double-labeled IF for Col II THD (red) and Col IIA (green) in P5 femora of WT (G) and *S1P^{cko}-Osx* (H). (I, J) TUNEL assay in P7 WT and *S1P^{cko}-Osx* distal femora. Apoptosis (arrow) is seen in green against DAPI-stained blue nuclei. (K, L) ISH analyses for *Col10a1* in P7 femoral growth plate in WT (K) and *S1P^{cko}-Osx* (L). Asterisks mark the presumptive SOC. Arrow points to regions of missing *Col10a1* expression in *S1P^{cko}-Osx* hypertrophic zone. (M-P) IF for Cxcl-12 (red) (M, N) and Gremlin1 (red) (O, P) in P21 mice. Arrow points to incomplete removal of cartilage from the epiphysis. (gp, growth plate; hz, hypertrophic zone; EB, epiphyseal bone; MB, metaphyseal bone). Scale bars: (A-F, I-L) 250 μ m; (G, H) 10 μ m; (M-P) 100 μ m.

osteolineages in growing and adult mice. This is in good standing with our observations that the biggest differences in bone development on S1P ablation in the *Osx* lineage is seen very early perinatally, a consequence of S1P ablation in fetal *Osx*⁺ perichondrial progenitors. While the mice are similar in size when born, P5 *S1P^{cko}-Osx* are easily detected due to their stunted growth, which becomes more pronounced at P7. Postnatally, the presence of GFP⁺ cells in the bone marrow of *S1P^{cko}-Osx* mice (missing in *Osx-Cre*/WT/*S1P^{+/f}-Osx*) and its size difference (much larger) from other cells in the bone marrow indicate that they are not of hematopoietic lineage, but a subpopulation of BMSCs. The expression of GFP indicates that these are *Osx*⁺ osteoprogenitors arrested at a specific stage of osteoblastogenesis that requires S1P. This rationale is further supported by the inability of BMSCs to differentiate into

osteoblasts *in vitro*, coupled with an inability to detect osteoblasts/bone lining cells *in vivo*. The similarity in the expression profile for *Col2a1*, *proColla1*, *Bglap* and *Alp* between the WT and *S1P^{+/f}-Osx*, along with similar values for CFU-F and SSCs and the absence of GFP⁺ cells indicate that their osteoblast differentiation program is normal, which is in contrast to the homozygous knockout *S1P^{cko}-Osx* mice. However, *in vitro*, *S1P^{+/f}-Osx* differs from WT in its inability to exhibit osteogenic differentiation, an aspect that presumably contributes to its smaller skeletal size than the WT. *S1P^{cko}-Osx* mice suffer from the double disadvantage that both bone (reduced CFU-F and SSCs and defective osteogenic differentiation) and chondrocyte (reduced growth plate thickness and hypertrophic zone) lineages are downregulated. As HCs can transdifferentiate into osteoblasts, the reduction of the hypertrophic zone in *S1P^{cko}-Osx* growth plate would

suggest a reduction in the number of HCs transdifferentiating to osteoblasts and therefore a reduction of chondrocyte contribution to osteoblast development. Thus, while there are different origins for postnatal bone, the bone formed in S1P^{cko-Osx} mice has drastically reduced contribution of Osx⁺ osteoprogenitors and, conceivably, HCs-derived osteoblasts.

S1P^{cko} mice are unable to make any endochondral bone (Patra et al., 2007). Though it did not prevent endochondral bone formation, S1P ablation in the *Osx* lineage decreased overall bone development drastically by downregulating SSC population and preventing their differentiation. Thus, in S1P^{cko}, it is possible that besides adversity from the abnormal cartilage, a defect in osteoprogenitors also contributed to the lack of endochondral bone formation. As most osteoblasts, CAR and CFU-F cells are descendants of *Col2-Cre*⁺ cells (Ono et al., 2014); S1P ablation by *Col2-Cre* may induce a stronger mutant phenotype as it targets a more diverse population of osteoprogenitors than *Osx-Cre*. As progenitors are derived from stem cells and *Col2a1* is expressed in bone marrow osteoprogenitors and not strictly in chondrocytes (Szabova et al., 2009; Wang et al., 2011), the reduction in *Col2a1* expression observed in the S1P^{cko-Osx} bone marrow presumably reflects the observed reductions in CFU-F and SSCs in these mice. These observations lend credence to the requirement of S1P in maintaining the SSC population in the murine bone marrow. S1P ablation in the *Osx* lineage, however, did not affect adipogenesis, indicating that this ablation did not interfere with other progenitor functions in the bone marrow. As S1P is not a secreted protein (Pullikotil et al., 2007), this observation may suggest that S1P ablation in the *Osx* lineage in the bone marrow does not cause non-cell autonomous mutational effects, in agreement with mosaic analysis in zebrafish (Schlombs et al., 2003). How S1P maintains the SSC population is not known as we have not yet identified a molecular target, but our studies clearly indicate a requirement for S1P in the *Osx* lineage for normal bone development.

The development of scoliosis in S1P^{cko-Osx} mice very early postnatally is reminiscent of adolescent idiopathic scoliosis (AIS) in humans (Lonstein, 1994). The etiology of scoliosis remains unknown although genetic predisposing factors likely contribute to this multifactorial disease. Scoliosis may arise in S1P^{cko-Osx} due to the reduction in BMD and consequent weak bones that cannot resist spine bending and/or twisting. Poor bone quality as an etiological factor in scoliosis remains controversial, but low BMD is a generalized phenomenon and a systematic disorder in AIS. The prevalence of AIS with osteoporosis is approximately 20–38% (Li et al., 2008). The associated osteochondrodysplasia and low BMD seen in S1P^{cko-Osx} mice suggests that it mimics the chondrodysplasia-related scoliosis seen in humans (Mason et al., 2002). Studies show that scoliosis can manifest due to gene deletions in osteochondroprogenitors; for example, the *Col2Cre*-directed deletion of *Neurofibromatosis type 1* gene (Wang et al., 2011) or *Src* *homology-2* gene (Kim et al., 2013). Thus, S1P-ablated mouse models are uniquely placed to investigate the molecular mechanisms for skeletal dysplasias and associated spine abnormalities and provide a genetic starting point to study and identify the molecular framework for investigating SSC differentiation to osteoblasts.

MATERIALS AND METHODS

Ethics statement

All mouse procedures were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, using vertebrate animals/ethics protocols reviewed and approved by the Animal Studies Committee at Washington University School of Medicine.

S1P ablation in the osterix lineage in mice

For mice with S1P ablation in the osterix (*Osx*) lineage, S1P^{fl/fl} mice (mice homozygous for the floxed *exon 2* of *Mbtps1*; in C57BL/6) (Yang et al., 2001) were bred with *Osx1-GFP::Cre* [Cre recombinase expressed as a fusion protein with GFP from the *Sp7* (*Osx*) promoter] (Rodda and McMahon, 2006) transgenic mice in the C57BL/6J strain to produce S1P^{+/fl}; *Osx-Cre* mice (mice heterozygous for S1P^{fl/fl} allele with *Osx-Cre* transgene). The heterozygous S1P^{+/fl}; *Osx-Cre* (S1P^{+/fl-Osx} or Het) mice were bred with S1P^{fl/fl} mice to generate mice with homozygous deletion of S1P (S1P^{fl/fl}; *Osx-Cre* or S1P^{cko-Osx} or Cko) in the *Osx* lineage. The *Osx1-GFP::Cre* (henceforth referred to as *Osx-Cre*) mice can be regulated by the tetracycline transactivator (tTA) that renders the *Osx* promoter inactive in the presence of doxycycline. In our studies, the mice were never fed doxycycline and therefore the *Osx-Cre* transgene was never temporally regulated by doxycycline. Genotypes were verified by PCR analysis of tail-derived DNA. As *Osx-Cre* mice have skeletal defects (Huang and Olsen, 2015), they were used as controls initially to confirm that the mutant phenotypes were caused by S1P ablation; otherwise, the heterozygote mice positive for *Osx-Cre* served as appropriate controls. Males and females showed identical phenotypes. However S1P^{cko-Osx} mice have difficulty surviving beyond weaning and require special and accessible food supplies to prolong their survival further for a short time (typically 7–8 days) post-weaning.

μCT

For μCT analyses, mice were skinned, eviscerated, and fixed in 10% neutral buffered formalin for 24–48 h, washed and stored in 70% ethanol. Skeletal elements were scanned in a VivaCT 40 scanner (Scanco Medical AG, Bruttisellen, Switzerland) at medium to high resolution and tube settings of 55 kV peak of energy, 145 μA of current with an integration time of 300 ms. Segmentation was performed to distinguish high density (bone) from low density (soft tissue/cartilage/growth plate) areas. Images from individual scan slices or reconstructed bones were captured as TIFF images. Morphometric measurements were calculated using 35–50 scan slices and the manufacturer's 3D analysis tools, and is based on the direct method of calculation (Hildebrand et al., 1999). Bone mineral density (BMD) heat maps were generated using OsiriX (Pixmeo SARL, Geneva, Switzerland) software and Jet color scheme, where yellowish-orange represents highest BMD and blue the lowest.

Dynamic histomorphometry

P21 mice were injected intraperitoneally with the fluorochrome calcein green (Sigma-Aldrich; 10 mg/kg) followed by alizarin complexone (Sigma-Aldrich; 30 mg/kg) 5 days later. Following alizarin administration, the hind limbs were harvested 2 days later and embedded in methyl methacrylate (Baron et al., 1983). Sections (10 μm thick) were visualized by fluorescent microscopy for calcein/alizarin incorporation. In these young mice, calcein-alizarin double labeling was observed primarily in the cortical bones. Dynamic histomorphometric measures such as mineral apposition rate (MAR), bone formation rate/bone surface (BFR/BS) and osteoclast surface/bone surface (Oc.S/BS) for the endosteal surface of the cortical bone was analyzed using Osteo II (BIOQUANT, Nashville, TN, USA).

qPCR analysis

For qPCR analysis, femur and tibia from hind limbs or calvariae were harvested, muscle and other tissues removed, and the bone marrow flushed out and analyzed separately. Bones and calvariae were pulverized in a Mikro-Dismembrator U (B. Braun Biotech International Melsungen, Germany) and RNA harvested using Trizol according to the manufacturer's recommended protocol and column purified by RNeasy mini kit (Qiagen). RNA (1 μg) was reverse transcribed into cDNA using a RT² First Strand kit (Qiagen) and the cDNA used for qPCR analysis using SYBR Green primer sets, 2X SYBR Green mix (Life Technologies/Applied Biosystems) using standard protocols and the relative amount of mRNA calculated using the comparative C_T method. As recommended by the MIQE standards for qPCR, normalization was performed using both murine *Gapdh* and *18S* genes. Both control genes yielded identical results. SYBR Green primer sets for the murine *18S* (Yoda et al., 2010), *Gapdh*, *proCol1a1*

(type I procollagen, $\alpha 1$), *Bglap* (osteocalcin) and alkaline phosphatase (*Alp*) are as previously reported (Zhang et al., 2011).

CFU-F assay

For CFU-F assays, the bone marrow was harvested from both hind limbs of P21 mice and red blood cells (RBCs) lysed using RBC lysis buffer (Sigma-Aldrich). Nucleated cells (1×10^6) were then plated in T75 cm² flasks and cultured for 2 days in α -MEM with 20% fetal bovine serum (FBS) and 2% penicillin/streptomycin. After 2 days, the medium was removed completely to remove dead cells, fresh medium added and cultured for a further 8 days, at which point colonies were stained with Methylene Blue. Only colonies that had at least 50 cells were counted as a viable colony.

FACS analysis for CD105⁺ SSCs

Analysis of LIN-negative (CD45⁻, Ter-119⁻), endothelial-negative (CD31⁻), CD105⁺ SSCs were done as described (Worthley et al., 2015). Briefly, long bones (stripped of skin and muscle tissue) from the hind limbs of P21 mice were harvested, crushed in a mortar and pestle with PBS and filtered using a 50 μ m filter. The sediment in the filter was digested with collagenase type IV (1.7 mg/ml) (Thermo Fisher Scientific) for 10 min at 37°C and mixed with filtrate from above. After several washings in PBS (with 0.1% bovine serum albumin), the cells were incubated with fluorescent-conjugated antibodies to CD45 (PE-Cy7) (552848, BD Pharmingen, San Jose, CA, USA), Ter-119 (PE-Cy7) (25-5921, eBioscience, San Diego, CA, USA), CD31 (BV421) (BD Pharmingen, 563356), and CD105 (Alexa Fluor 647) (562761, BD Pharmingen) and FACS analysis performed on BD FACS Aria following standard protocols. In gating analysis (performed by FlowJo_V10; www.flowjo.com), single cells were gated negatively for PE-Cy7 signals (CD45- and Ter-119-expressing) to remove hematopoietic and erythrocyte cells, followed by negative gating for BV421 signals (CD31-expressing) to remove endothelial cells from the population of CD105⁺ cells (Alexa Fluor 647 signals).

In vitro osteogenic and adipogenic differentiation assays

Bone marrow was harvested from the hind limbs of P21 mice and the resulting cell population obtained after lysis of RBCs were cultured in a single well of a six-well plate in α -MEM with 20% FBS and 2% penicillin/streptomycin until confluent. Once confluent, cells were passaged into a 6 cm dish and cultured until confluent. The cells were then cultured in two wells of a six-well plate, grown until confluent at which point osteogenic differentiation media (α -MEM with 10% FBS, 2% penicillin/streptomycin, 10 mM β -glycerolphosphate, 50 μ g/ml of ascorbic acid) was added and cultured for 14 days. Osteogenic differentiation was assessed by silver staining of the mineralized matrix by the von Kossa method. For adipogenic differentiation, cells obtained after lysis of RBCs were cultured in a single well of a six-well plate in complete MesenCult™ Expansion medium (STEMCELL Technologies, Vancouver, Canada) at 37°C under hypoxic conditions until 80-90% confluent. The medium was then replaced with complete MesenCult™ Adipogenic Medium (STEMCELL Technologies), and the cells were incubated further at 37°C in hypoxic conditions with a change in medium every 3 days for a total of 14 days. Adipogenic differentiation was analyzed by staining for lipid droplets by Oil Red O.

ISH analysis

ISH analyses were performed on 5- μ m paraffin-embedded sections as described previously using ³⁵S-labeled riboprobes (Long et al., 2001; Patra et al., 2007). ISH images were viewed with a BX51 microscope (Olympus, Waltham, MA, USA) and images captured with a digital camera (DP70; Olympus) using DP controller software (Olympus). Images of hybridization signals were pseudo-colored red and superimposed on Toluidine Blue-counterstained images using Photoshop (Adobe).

Antibodies, immunofluorescence, and imaging

Western blot analysis for Akt (9272, Cell Signaling Technology), phospho-Akt (9271, Cell Signaling Technology), GSK-3 β (9315, Cell Signaling Technology), phospho-GSK-3 β (9323, Cell Signaling Technology), and β -catenin (sc-7199, Santa Cruz Biotechnology) proteins in protein lysates

from E14.5 hind limbs were performed as described (Duan et al., 2015). Antibodies to the type II collagen (Col II) triple helical domain (THD), type IIA procollagen (Col IIA) and the type IIB procollagen (pro-Col IIB) and their use in double-labeled IF to analyze the cartilage matrix are as reported (Patra et al., 2014a, 2007). IF for PECAM-1, Runx2, type I collagen (Col I), osteocalcin, Cxcl-12 and Gremlin1 proteins was performed on frozen hind limb sections after fixing tissues overnight with 4% formaldehyde (Duan et al., 2015). Antibody concentrations were as follows: antibodies to PECAM-1 (BD Biosciences), osteocalcin (ab93876, Abcam), Gremlin1 (sc-18274, Santa Cruz Biotechnology) and Cxcl-12 (ab18919, Abcam) were used at 1:50; antibodies to Runx2 (ab23981, Abcam) and Col I (ab21286, Abcam) were used at 1:250 and 1:100, respectively. Secondary antibodies (Life Technologies) were Alexa Fluor 594-conjugated donkey anti-rabbit (A-21207) or anti-rat (A-21209), used at 1:250. Signal amplification using a TSA kit (Thermo Fisher Scientific) was used for osteocalcin and Gremlin1 antibodies only. All antibodies were tested and validated for specific staining and showed negligible background staining. Images were captured using a 60 \times , 1.4 NA oil immersion objective mounted on an Eclipse E800 microscope (Nikon, Melville, NY, USA) and QImaging Retiga 2000R Fast 1394 camera and deconvolved. For deconvolution imaging, MetaMorph software (Molecular Devices) was used to control the Z-motor device (Prior Scientific, Cambridge, UK), and also to capture, deconvolve images and compile them to give a final image.

Apoptosis assays

Detection of apoptosis on formalin-fixed tissues was performed by TUNEL assay using the *in situ* cell death detection kit (Roche) according to the manufacturer's instructions. Analysis of apoptosis in the mouse bone marrow (with or without lysis of red blood cells) was performed by labeling bone marrow cells harvested from P21 hind limbs with Andy Fluor 647-Annexin V conjugate (GeneCopoeia, Rockville, MD, USA) to detect the presence of external phosphatidylserines on the surface of cells induced by apoptosis, following the manufacturer's recommended protocol. Detection of fluorescent signals was performed on BD LSR II followed by analysis using FlowJo_V10.

Statistical analysis

Statistical data are reported as mean \pm s.d. A two-tailed Student's *t*-test was used to compute values. *P*<0.05 is considered statistically significant. Number of mice per genotype (*N*) in each data set is reported in figure legends.

Acknowledgements

We thank Crystal Idleburg of the In Situ Molecular Analysis subdivision of Washington University's Musculoskeletal Research Center for her assistance with histological analysis, and Sahil Mahajan and Rafael Czepielewski for their assistance with FACS analysis.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: D.P.; Methodology: D.P., E.D., J.M., G.A.-E.; Validation: D.P., E.D.; Formal analysis: D.P., L.J.S.; Investigation: D.P., E.D., J.M., G.A.-E.; Data curation: D.P.; Writing - original draft: D.P.; Writing - review & editing: D.P., L.J.S.; Visualization: D.P.; Supervision: D.P.; Project administration: D.P.; Funding acquisition: D.P., L.J.S.

Funding

This work was supported by the Scoliosis Research Society (SRS-K2M Standard Investigator Research Grant to D.P.) and the National Institutes of Health (RO1 AR066590 to D.P. and L.J.S.; P30 AR057235 to the Musculoskeletal Research Center at Washington University).

Supplementary information

Supplementary information available online at <http://bio.biologists.org/lookup/doi/10.1242/bio.032094.supplemental>

References

Baron, R., Vignery, A., Neff, L., Silvergate, A. and Santa Maria, A. (1983). Processing of undecalcified bone specimens for bone histomorphometry. In *Bone*

- Histomorphometry: Techniques and Interpretation* (ed. R. R. Recker), pp. 13-35. Boca Raton: CRC Press, Inc.
- Brown, M. S. and Goldstein, J. L. (1999). A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *Proc. Natl. Acad. Sci. USA* **96**, 11041-11048.
- Brown, M. S., Ye, J., Rawson, R. B. and Goldstein, J. L. (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. *Cell* **100**, 391-398.
- Chan, C. K. F., Seo, E. Y., Chen, J. Y., Lo, D., McArdle, A., Sinha, R., Tevlin, R., Seita, J., Vincent-Tompkins, J., Wearda, T. et al. (2015). Identification and specification of the mouse skeletal stem cell. *Cell* **160**, 285-298.
- Chen, J., Shi, Y., Regan, J., Karuppaiah, K., Ornitz, D. M. and Long, F. (2014). *Osx-Cre* targets multiple cell types besides osteoblast lineage in postnatal mice. *PLoS ONE* **9**, e85161.
- Duan, X., Murata, Y., Liu, Y., Nicolae, C., Olsen, B. R. and Berendsen, A. D. (2015). Vegfa regulates perichondral vascularity and osteoblast differentiation in bone development. *Development* **142**, 1984-1991.
- Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L. and Karsenty, G. (1997). *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* **89**, 747-754.
- Eberlé, D., Hegarty, B., Bossard, P., Ferré, P. and Foulle, F. (2004). SREBP transcription factors: master regulators of lipid homeostasis. *Biochimie* **86**, 839-848.
- Hildebrand, T., Laib, A., Müller, R., Dequeker, J. and Rüegsegger, P. (1999). Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. *J. Bone Miner. Res.* **14**, 1167-1174.
- Hill, T. P., Später, D., Taketo, M. M., Birchmeier, W. and Hartmann, C. (2005). Canonical Wnt/ β -catenin signaling prevents osteoblasts from differentiating into chondrocytes. *Dev. Cell* **8**, 727-738.
- Hu, H., Hilton, M. J., Tu, X., Yu, K., Ornitz, D. M. and Long, F. (2005). Sequential roles of Hedgehog and Wnt signaling in osteoblast development. *Development* **132**, 49-60.
- Huang, W. and Olsen, B. R. (2015). Skeletal defects in *Osterix-Cre* transgenic mice. *Transgenic Res.* **24**, 167-172.
- Kim, H. K., Aruwajoye, O., Sucato, D., Richards, B. S., Feng, G. S., Chen, D., King, P. and Kamiya, N. (2013). Induction of SHP2-deficiency in chondrocytes causes severe scoliosis and kyphosis in mice. *Spine (Phila Pa 1976)* **38**, E1307-E1312.
- Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M. et al. (1997). Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* **89**, 755-764.
- Kostopoulou, F., Gkretsi, V., Malizos, K. N., Iliopoulos, D., Oikonomou, P., Poulosides, L. and Tsezou, A. (2012). Central role of SREBP-2 in the pathogenesis of osteoarthritis. *PLoS ONE* **7**, e35753.
- Li, X.-F., Li, H., Liu, Z.-D. and Dai, L.-Y. (2008). Low bone mineral status in adolescent idiopathic scoliosis. *Eur. Spine J.* **17**, 1431-1440.
- Lindert, U., Cabral, W. A., Ausavarat, S., Tongkobpetch, S., Ludin, K., Barnes, A. M., Yeetong, P., Weis, M., Krabichler, B., Srichomthong, C. et al. (2016). MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. *Nat. Commun.* **7**, 11920.
- Long, F., Zhang, X. M., Karp, S., Yang, Y. and McMahon, A. P. (2001). Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. *Development* **128**, 5099-5108.
- Lonstein, J. E. (1994). Adolescent idiopathic scoliosis. *Lancet* **344**, 1407-1412.
- Maes, C., Kobayashi, T., Selig, M. K., Torrekens, S., Roth, S. I., Mackem, S., Carmeliet, G. and Kronenberg, H. M. (2010). Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev. Cell* **19**, 329-344.
- Marschner, K., Kollmann, K., Schweizer, M., Bräulke, T. and Pohl, S. (2011). A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism. *Science* **333**, 87-90.
- Mason, D. E., Sanders, J. O., MacKenzie, W. G., Nakata, Y. and Winter, R. (2002). Spinal deformity in chondrodysplasia punctata. *Spine (Phila Pa 1976)* **27**, 1995-2002.
- Mizoguchi, T., Pinho, S., Ahmed, J., Kunisaki, Y., Hanoun, M., Mendelson, A., Ono, N., Kronenberg, H. M. and Frenette, P. S. (2014). *Osterix* marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Dev. Cell* **29**, 340-349.
- Murakami, T., Saito, A., Hino, S.-I., Kondo, S., Kanemoto, S., Chihara, K., Sekiya, H., Tsumagari, K., Ochiai, K., Yoshinaga, K. et al. (2009). Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. *Nat. Cell Biol.* **11**, 1205-1211.
- Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R. and de Crombrughe, B. (2002). The novel zinc finger-containing transcription factor *osterix* is required for osteoblast differentiation and bone formation. *Cell* **108**, 17-29.
- Nishimura, R., Wakabayashi, M., Hata, K., Matsubara, T., Honma, S., Wakisaka, S., Kiyonari, H., Shioi, G., Yamaguchi, A., Tsumaki, N. et al. (2012). *Osterix* regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification. *J. Biol. Chem.* **287**, 33179-33190.
- Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno, K. and Nagasawa, T. (2010). The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. *Immunity* **33**, 387-399.
- Ono, N., Ono, W., Nagasawa, T. and Kronenberg, H. M. (2014). A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. *Nat. Cell Biol.* **16**, 1157-1167.
- Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., Stamp, G. W. H., Beddington, R. S. P., Mundlos, S., Olsen, B. R. et al. (1997). *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* **89**, 765-771.
- Park, J., Gebhardt, M., Golovchenko, S., Perez-Branguli, F., Hattori, T., Hartmann, C., Zhou, X., deCrombrughe, B., Stock, M., Schneider, H. et al. (2015). Dual pathways to endochondral osteoblasts: a novel chondrocyte-derived osteoprogenitor cell identified in hypertrophic cartilage. *Biol. Open* **4**, 608-621.
- Patra, D., Xing, X., Davies, S., Bryan, J., Franz, C., Hunziker, E. B. and Sandell, L. J. (2007). Site-1 protease is essential for endochondral bone formation in mice. *J. Cell Biol.* **179**, 687-700.
- Patra, D., DeLassus, E., Hayashi, S. and Sandell, L. J. (2011). Site-1 protease is essential to growth plate maintenance and is a critical regulator of chondrocyte hypertrophic differentiation in postnatal mice. *J. Biol. Chem.* **286**, 29227-29240.
- Patra, D., DeLassus, E., Liang, G. and Sandell, L. J. (2014a). Cartilage-specific ablation of site-1 protease in mice results in the endoplasmic reticulum entrapment of type IIb procollagen and down-regulation of cholesterol and lipid homeostasis. *PLoS ONE* **9**, e105674.
- Patra, D., DeLassus, E., McAlinden, A. and Sandell, L. J. (2014b). Characterization of a murine type IIb procollagen-specific antibody. *Matrix Biol.* **34**, 154-160.
- Pullikotil, P., Benjannet, S., Mayne, J. and Seidah, N. G. (2007). The proprotein convertase SKI-1/S1P: alternate translation and subcellular localization. *J. Biol. Chem.* **282**, 27402-27413.
- Rodda, S. J. and McMahon, A. P. (2006). Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. *Development* **133**, 3231-3244.
- Schlombs, K., Wagner, T. and Scheel, J. (2003). Site-1 protease is required for cartilage development in zebrafish. *Proc. Natl. Acad. Sci. USA* **100**, 14024-14029.
- Szabova, L., Yamada, S. S., Wimer, H., Chrysosvergis, K., Ingvarsen, S., Behrendt, N., Engelholm, L. H. and Holmbeck, K. (2009). MT1-MMP and type II collagen specify skeletal stem cells and their bone and cartilage progeny. *J. Bone Miner. Res.* **24**, 1905-1916.
- Wang, W., Nyman, J. S., Ono, K., Stevenson, D. A., Yang, X. and Eleftheriou, F. (2011). Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. *Hum. Mol. Genet.* **20**, 3910-3924.
- Worthley, D. L., Churchill, M., Compton, J. T., Taylor, Y., Rao, M., Si, Y., Levin, D., Schwartz, M. G., Uygur, A., Hayakawa, Y. et al. (2015). Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. *Cell* **160**, 269-284.
- Yang, J., Goldstein, J. L., Hammer, R. E., Moon, Y.-A., Brown, M. S. and Horton, J. D. (2001). Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. *Proc. Natl. Acad. Sci. USA* **98**, 13607-13612.
- Yang, L., Tsang, K. Y., Tang, H. C., Chan, D. and Cheah, K. S. E. (2014). Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. *Proc. Natl. Acad. Sci. USA* **111**, 12097-12102.
- Yoda, E., Hachisu, K., Taketomi, Y., Yoshida, K., Nakamura, M., Ikeda, K., Taguchi, R., Nakatani, Y., Kuwata, H., Murakami, M. et al. (2010). Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca^{2+} -independent phospholipase A2gamma-deficient mice. *J. Lipid Res.* **51**, 3003-3015.
- Zhang, Y., Xie, R.-L., Croce, C. M., Stein, J. L., Lian, J. B., van Wijnen, A. J. and Stein, G. S. (2011). A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. *Proc. Natl. Acad. Sci. USA* **108**, 9863-9868.
- Zhou, X., von der Mark, K., Henry, S., Norton, W., Adams, H. and de Crombrughe, B. (2014). Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. *PLoS Genet.* **10**, e1004820.